ArticleiScience2026
CPS1 promotes colorectal cancer progression by inducing EMT and activating TGF-β/Smad signaling pathway.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a highly lethal digestive malignancy, particularly in metastatic cases. Carbamoyl-phosphate synthase 1 (CPS1), a key mitochondrial enzyme involved in the urea cycle, has been implicated in multiple cancers. However, its role in CRC remains poorly understood. This study demonstrated that CPS1 expression was significantly upregulated in CRC tissues and was associated with aggressive clinicopathological characteristics and poor prognosis. Functional experiments revealed that CPS1 knockdown markedly suppressed CRC cell proliferation, migration, invasion, and tumorigenicity, whereas CPS1 overexpression exerted opposite effects. Mechanistically, CPS1 downregulation increased E-cadherin expression and decreased the expression of ZEB1, slug, N-cadherin, vimentin, MMP2, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.